Quantcast

Pharma news

Global Anticoagulants Reversal Drugs Market Covering Key Players & Their Competitive Strategies, 2019: Analysis & Outlook Through 2018-2026 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Anticoagulants Reversal Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies

Posted in news | Leave a comment

Global Anticoagulants Reversal Drugs Market Covering Key Players & Their Competitive Strategies, 2019: Analysis & Outlook Through 2018-2026 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Anticoagulants Reversal Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies

Posted in news | Leave a comment

Anterior Uveitis – Pipeline Insight, 2019 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Anterior Uveitis – Pipeline Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering. The report offers comprehensive

Posted in news | Leave a comment

Worldwide Chemotherapy Drugs Market Outlook to 2023 – Featuring Pfizer, Eli Lilly, Celgene, Bristol-Myers Squibb, Merck & Co, GlaxoSmithKline, Novartis, Sanofi, and Teva Pharmaceutical Industries – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Chemotherapy Drugs Market: Analysis By Drug Type (Antimetabolites, Plant Alkaloids, Alkylating Agents, Antitumor Antibiotics), By Administration (Oral,

Posted in news | Leave a comment

Pfizer and Lilly Announce Top-Line Results From Long-Term Phase 3 Study of Tanezumab in Patients With Osteoarthritis

NEW YORK & INDIANAPOLIS–(BUSINESS WIRE)–Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced top-line results from a Phase

Posted in news | Leave a comment

Innovus Pharma Announces FDA Approval of New ANDA for Supply of FlutiCare®

Company Also Reaches Sales Milestone of 1,000 Units of FlutiCare® Sold per Day SAN DIEGO–(BUSINESS WIRE)–Innovus Pharmaceuticals, Inc. (“Innovus Pharma”

Posted in news | Leave a comment

Grossly Misleading “Short and Distort” Article Wrongfully Attempts to Dupe 22nd Century Group Shareholders

22nd Century exposes short seller as a promotor of incorrect and self-serving “fake news” WILLIAMSVILLE, N.Y.–(BUSINESS WIRE)–22nd Century Group, Inc.

Posted in news | Leave a comment

Global Pharmacovigilance Market by Clinical Trial Phase, Service Provider, Type, End-use and Region – Forecast to 2026 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Pharmacovigilance Market Size, Share & Trends Analysis Report By Clinical Trial Phase (Pre-Clinical, Phase I, II, III, IV),

Posted in news | Leave a comment

Global $15.63Bn Stem Cell Market by Product, Application, Technology, Therapy, and Region – Forecast to 2025 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Stem Cell Market Size Analysis Report By Product (Adult, hESC, Induced Pluripotent), By Application (Regenerative Medicine, Drug Discovery

Posted in news | Leave a comment

BioKansas to Host the 2019 Kansas BioGENEius Challenge Finals and Networking Reception on Thursday, April 25th

FAIRWAY, Kan.–(BUSINESS WIRE)–BioKansas is hosting the 2019 Kansas BioGENEius Challenge Finals on Thursday, April 25th, at the KU Edwards Campus.

Posted in news | Leave a comment

Eisai, Biogen kick-off phase 3 testing early Alzheimer’s disease antibody, amid dropping aducanunab trial. Eisai’s US company presents AD pipeline

Eisai Co said Friday thata global Phase III clinical study (Clarity AD/Study 301) of BAN2401, an anti-amyloid beta protofibril antibody, in patients with early Alzheimer’s disease has been initiated.

Posted in Approval, Asia, Europe, North America, Regions | Tagged , , | Leave a comment

ProMIS offeri potential significant advantage over aducanumab, learns from mistakes

ProMIS Neurosciencesissued a pres release Friday, raising urgency to selectively target the toxic oligomer with exacting precision as part of the global effort to develop disease-modifying therapies for Alzheimer’s disease (AD), upon Biogen’s and Eisai’s dropping two alte-stage clinical trials of aducanumab.

Posted in Approval, North America | Tagged , , , , | Leave a comment

Alvogen’s Taiwan company – Lotus – exchange stake with Fuji Pharma

@alvogenpr subsidiary in Taiwan, Lotus Pharmaceuticals today announced capital and business collaboration agreements with Fuji Pharma in Japan, as Fuji has acquired a 2.0% stake in Lotus for approximately US$20 million (or NT$ 617 million, JPY 2.2 billion). Lotus has also acquired 3.9% stake in Fuji for an equal sum.

Posted in Approval, Asia, Europe, news | Tagged , , | Leave a comment

Gelesis Announces Three Presentations at Annual Endocrine Society Meeting

BOSTON–(BUSINESS WIRE)–Gelesis, a biotechnology company developing first-in-class mechanotherapeutics to treat obesity and other chronic diseases related to the gastrointestinal (GI)

Posted in Approval, news, North America | Tagged | Leave a comment

CB Therapeutics Secures new Research and Production Facility

SAN DIEGO–(BUSINESS WIRE)–CB Therapeutics is an innovative biotechnology company focusing on research and production of cannabinoids. The company utilizes its

Posted in Approval, news | Tagged | Leave a comment

Vaxart Announces Closing of Registered Direct Offering of Common Stock

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather

Posted in Approval, news, North America | Tagged | Leave a comment

First Cancer Patient Receives Dose of Super-Enhancer Inhibitor GZ17-6.02, an Advanced Cancer Drug from Genzada Pharmaceuticals, at HonorHealth Research Institute

STERLING, Kan.–(BUSINESS WIRE)–Genzada Pharmaceuticals USA Inc. (Genzada), a subsidiary of Ionics Life Sciences Limited, announced today that the first patient

Posted in Approval, news, North America, Regions | Tagged , , , , , | Leave a comment

Transgene: A Positive 2018, Moving Ahead with a Strong Portfolio

2018 Full-year results and business update Clinical trials set to announce key data in 2019 Invir.IO™ platform designed to deliver

Posted in Approval, news | Tagged | Leave a comment

Center for Gene and Cell Therapy Co-founded by Miltenyi and ATLATL in Shanghai

SHANGHAI–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/Shanghai?src=hash" target="_blank"gt;#Shanghailt;/agt;–To accelerate the development of cell and gene therapy, ATLATL Center and Miltenyi Biotec have cooperated to build ATLATL-MACS Center

Posted in Approval, Asia, news, Regions | Tagged | Leave a comment

MichBio Announces 7th Annual “Michigan Biosciences Day at the Capitol,” Seeks Participants

ANN ARBOR, Mich. & LANSING, Mich.–(BUSINESS WIRE)–Michigan’s premier biosciences industry trade organization, MichBio, presents its annual Michigan Biosciences Day at

Posted in Approval, news | Tagged | Leave a comment